Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

Y0001601

Alfacalcidol for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

1α-Hydroxyvitamin D3, 1α-Hydroxycholecalciferol, Alfacalcidol

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C27H44O2
Numéro CAS:
Poids moléculaire :
400.64
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24

Source biologique

synthetic

Qualité

pharmaceutical primary standard

Agence

EP

Forme

solid

Fabricant/nom de marque

EDQM

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

−20°C

Chaîne SMILES 

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C

InChI

1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1

Clé InChI

OFHCOWSQAMBJIW-AVJTYSNKSA-N

Informations sur le gène

human ... VDR(7421)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Synthetic vitamin D3 analog that is metabolized to 1,25-dihydroxycholecalciferol. Inhibits bone resorption and stimulates bone formation. Supresses parathyroid hormone secretion by bovine parathyroid cells.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Skull and crossbones

Mention d'avertissement

Danger

Mentions de danger

Conseils de prudence

Classification des risques

Acute Tox. 1 Oral

Code de la classe de stockage

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Vitamin D and metabolites measurement by tandem mass spectrometry
van den Ouweland JMW, et al.
Reviews in Endocrine & Metabolic Disorders, 14(2), 159-184 (2013)
Novel approach for the determination of alfacalcidol in bulk and tablet dosage form using spectrophotometric method
Saeed-Ul-Hassan S, et al.
Latin American Journal of Pharmacy, 32(5), 784-788 (2013)
The use of alfacalcidol in the prevention of bone disease in early renal failure.
J A Kanis
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 10 Suppl 4, 23-28 (1995-01-01)
Ayako Shiraishi et al.
The Journal of steroid biochemistry and molecular biology, 144 Pt A, 119-123 (2013-11-06)
Eldecalcitol (ELD), a 2β-hydroxypropyloxy derivative of 1α,25(OH)2D3, is a potent inhibitor of bone resorption that has demonstrated a greater effect at reducing the risk of fracture in osteoporotic patients than alfacalcidol (ALF). In the present study, we used the senescence-accelerated
E Schacht
Calcified tissue international, 65(4), 317-327 (1999-09-15)
Increased cytokine release and increased activity of osteoclasts (reduced osteoclast apoptosis) due to a fall in estrogen is of causal significance in postmenopausal bone loss as well as malfunction of the vitamin D activation and concomitant calcium (Ca) malabsorption. Alfacalcidol

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique